IBDEI10J ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16288,0)
 ;;=F52.8^^88^876^104
 ;;^UTILITY(U,$J,358.3,16288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16288,1,3,0)
 ;;=3^Sexual Dysfnct Not d/t Substance/Known Physiological Cond
 ;;^UTILITY(U,$J,358.3,16288,1,4,0)
 ;;=4^F52.8
 ;;^UTILITY(U,$J,358.3,16288,2)
 ;;=^5003624
 ;;^UTILITY(U,$J,358.3,16289,0)
 ;;=F52.21^^88^876^33
 ;;^UTILITY(U,$J,358.3,16289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16289,1,3,0)
 ;;=3^Erectile Disorder,Male (Psychogenic)
 ;;^UTILITY(U,$J,358.3,16289,1,4,0)
 ;;=4^F52.21
 ;;^UTILITY(U,$J,358.3,16289,2)
 ;;=^5003620
 ;;^UTILITY(U,$J,358.3,16290,0)
 ;;=I12.9^^88^876^59
 ;;^UTILITY(U,$J,358.3,16290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16290,1,3,0)
 ;;=3^Hypertensive Kidney Disease Chronic w/ Stg 1-4
 ;;^UTILITY(U,$J,358.3,16290,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,16290,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,16291,0)
 ;;=N04.9^^88^876^76
 ;;^UTILITY(U,$J,358.3,16291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16291,1,3,0)
 ;;=3^Nephrotic Syndrome w/ Unspec Morphologic Changes
 ;;^UTILITY(U,$J,358.3,16291,1,4,0)
 ;;=4^N04.9
 ;;^UTILITY(U,$J,358.3,16291,2)
 ;;=^5015540
 ;;^UTILITY(U,$J,358.3,16292,0)
 ;;=N02.9^^88^876^53
 ;;^UTILITY(U,$J,358.3,16292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16292,1,3,0)
 ;;=3^Hematuria w/ Unspec Morphologic Changes,Recurrent & Persistent
 ;;^UTILITY(U,$J,358.3,16292,1,4,0)
 ;;=4^N02.9
 ;;^UTILITY(U,$J,358.3,16292,2)
 ;;=^5015520
 ;;^UTILITY(U,$J,358.3,16293,0)
 ;;=N06.9^^88^876^93
 ;;^UTILITY(U,$J,358.3,16293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16293,1,3,0)
 ;;=3^Proteinuria Isolated w/ Unspec Morphologic Lesion
 ;;^UTILITY(U,$J,358.3,16293,1,4,0)
 ;;=4^N06.9
 ;;^UTILITY(U,$J,358.3,16293,2)
 ;;=^5015558
 ;;^UTILITY(U,$J,358.3,16294,0)
 ;;=N05.9^^88^876^73
 ;;^UTILITY(U,$J,358.3,16294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16294,1,3,0)
 ;;=3^Nephritic Syndrome w/ Unspec Morphologic Changes
 ;;^UTILITY(U,$J,358.3,16294,1,4,0)
 ;;=4^N05.9
 ;;^UTILITY(U,$J,358.3,16294,2)
 ;;=^5134086
 ;;^UTILITY(U,$J,358.3,16295,0)
 ;;=N07.9^^88^876^75
 ;;^UTILITY(U,$J,358.3,16295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16295,1,3,0)
 ;;=3^Nephropathy Hereditary w/ Unspec Morphologic Lesions
 ;;^UTILITY(U,$J,358.3,16295,1,4,0)
 ;;=4^N07.9
 ;;^UTILITY(U,$J,358.3,16295,2)
 ;;=^5015568
 ;;^UTILITY(U,$J,358.3,16296,0)
 ;;=N15.9^^88^876^100
 ;;^UTILITY(U,$J,358.3,16296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16296,1,3,0)
 ;;=3^Renal Tubulo-Interstitial Disease,Unspec
 ;;^UTILITY(U,$J,358.3,16296,1,4,0)
 ;;=4^N15.9
 ;;^UTILITY(U,$J,358.3,16296,2)
 ;;=^5015596
 ;;^UTILITY(U,$J,358.3,16297,0)
 ;;=N17.9^^88^876^65
 ;;^UTILITY(U,$J,358.3,16297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16297,1,3,0)
 ;;=3^Kidney Failure,Acute,Unspec
 ;;^UTILITY(U,$J,358.3,16297,1,4,0)
 ;;=4^N17.9
 ;;^UTILITY(U,$J,358.3,16297,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,16298,0)
 ;;=N19.^^88^876^66
 ;;^UTILITY(U,$J,358.3,16298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16298,1,3,0)
 ;;=3^Kidney Failure,Unspec
 ;;^UTILITY(U,$J,358.3,16298,1,4,0)
 ;;=4^N19.
 ;;^UTILITY(U,$J,358.3,16298,2)
 ;;=^5015607
 ;;^UTILITY(U,$J,358.3,16299,0)
 ;;=N11.0^^88^876^97
 ;;^UTILITY(U,$J,358.3,16299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16299,1,3,0)
 ;;=3^Pyelonephritis,Chronic Nonobstructive Reflux-Associated
 ;;^UTILITY(U,$J,358.3,16299,1,4,0)
 ;;=4^N11.0
